---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-007871"
form_type: "8-K"
ticker: "PMCB"
cik: "0001157075"
company_name: "PharmaCyte Biotech, Inc."
filed_at: "2025-10-31T23:59:59+00:00"
generated_at: "2026-05-17T01:04:01.586128+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# PharmaCyte stockholders authorize share issuance and approve 2.25M share increase to equity plan

## Summary
- Stockholders authorized issuance of shares underlying convertible preferred stock and warrants per August 2025 SPA (1,649,395 for, 249,100 against).
- Amendment to 2022 Equity Incentive Plan approved, increasing share reserve by 2,250,000 shares (2,348,827 for, 399,696 against).
- All three proposals passed at special meeting on Oct 30, 2025, with ~37.1% quorum (2,866,944 shares voted).
- Proposal 3 (adjournment) also passed: 2,496,898 for, 311,836 against, 58,210 abstentions.

## SEC filing metadata
- accession: 0001683168-25-007871
- form_type: 8-K
- ticker: PMCB
- cik: 0001157075
- company_name: PharmaCyte Biotech, Inc.
- filed_at: 2025-10-31T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157075/000168316825007871/0001683168-25-007871-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157075/000168316825007871/pharmacyte_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-007871
- JSON: https://secwatch.observer/filing/0001683168-25-007871.json
- Plain text: https://secwatch.observer/filing/0001683168-25-007871.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.